Conditions: Corneal Neovascularization
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 24
Healthy volunteers: yes

Brief summary:
Purpose: To determine the efficacy and safety of one commonly used VEGF inhibitor, bevacizumab (Avastin, Genentech), as a topical agent for the treatment of corneal neovascularization.

Detailed description:

Arms:

Interventions: intervention 1: Bevacizumab (Avastin)
Intervention descriptions: intervention 1: Bevacizumab 10mg/mL 1 drop BID x 3 weeks

Protocol document: